Melanom: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma

Stadium/Indikation inkl. Kurzinfo

Adjuvant, Melanom Stadium III-IV

Relatlimab + Nivolumab
vs
Nivolumab

Kurztitel

BMSCA224-098
(RELATIVITY 098)
NCT05002569

Offizieller Titel

A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma